Meeting
2016 ASCO Annual Meeting
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
Authors
Yasutoshi Kuboki
Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Yasutoshi Kuboki , Tomohiro Nishina , Kensei Yamaguchi , Eiji Shinozaki , Yoshito Komatsu , Satoshi Yuki , Kentaro Yamazaki , Hiroki Hara , Miki Fukutani , Yasue Uchida , Natsuko Tsukahara , Hiromi Hasegawa , Seiko Matsuda , Wataru Okamoto , Masahito Yonemura , Shogo Nomura , Akihiro Sato , Atsushi Ohtsu , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
000017114
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS3632)
DOI
10.1200/JCO.2016.34.15_suppl.TPS3632
Abstract #
TPS3632
Poster Bd #
325a
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
First Author: Patrick McKay Boland
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2018 ASCO Annual Meeting
A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
First Author: Patrick McKay Boland
Poster
2014 Gastrointestinal Cancers Symposium
Phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pretreated patients with metastatic colorectal cancer.
First Author: Kazuhisa Yamaguchi